Literature DB >> 22698405

A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma.

Claudio De Vito1, Nicolo Riggi, Sandrine Cornaz, Mario-Luca Suvà, Karine Baumer, Paolo Provero, Ivan Stamenkovic.   

Abstract

We have recently demonstrated that human pediatric mesenchymal stem cells can be reprogrammed toward a Ewing sarcoma family tumor (ESFT) cancer stem cell (CSC) phenotype by mechanisms that implicate microRNAs (miRNAs). Here, we show that the miRNA profile of ESFT CSCs is shared by embryonic stem cells and CSCs from divergent tumor types. We also provide evidence that the miRNA profile of ESFT CSCs is the result of reversible disruption of TARBP2-dependent miRNA maturation. Restoration of TARBP2 activity and systemic delivery of synthetic forms of either of two of its targets, miRNA-143 or miRNA-145, inhibited ESFT CSC clonogenicity and tumor growth in vivo. Our observations suggest that CSC self-renewal and tumor maintenance may depend on deregulation of TARBP2-dependent miRNA expression.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22698405     DOI: 10.1016/j.ccr.2012.04.023

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  44 in total

Review 1.  Dysregulation of microRNA biogenesis machinery in cancer.

Authors:  Akiko Hata; Risa Kashima
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-12-01       Impact factor: 8.250

2.  Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.

Authors:  Srikanth R Ambati; Eloisi Caldas Lopes; Kohji Kosugi; Ullas Mony; Ahmet Zehir; Smit K Shah; Tony Taldone; Andre L Moreira; Paul A Meyers; Gabriela Chiosis; Malcolm A S Moore
Journal:  Mol Oncol       Date:  2013-12-15       Impact factor: 6.603

3.  Up-regulation and worse prognostic marker of cytoplasmic TARBP2 expression in obstinate breast cancer.

Authors:  Xiaoti Lin; Minqing Wu; Peng Liu; Fengqin Wei; Laisheng Li; Hailin Tang; Xinhua Xie; Xiaoping Liu; Lu Yang; Xiaoming Xie
Journal:  Med Oncol       Date:  2014-02-22       Impact factor: 3.064

Review 4.  MicroRNA biogenesis pathways in cancer.

Authors:  Shuibin Lin; Richard I Gregory
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

Review 5.  The role of TARBP2 in the development and progression of cancers.

Authors:  Xin Yu; Zheng Li
Journal:  Tumour Biol       Date:  2015-10-20

6.  Metastasis-suppressor transcript destabilization through TARBP2 binding of mRNA hairpins.

Authors:  Hani Goodarzi; Steven Zhang; Colin G Buss; Lisa Fish; Saeed Tavazoie; Sohail F Tavazoie
Journal:  Nature       Date:  2014-07-09       Impact factor: 49.962

7.  Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.

Authors:  Michelle Marques Howarth; David Simpson; Siu P Ngok; Bethsaida Nieves; Ron Chen; Zurab Siprashvili; Dedeepya Vaka; Marcus R Breese; Brian D Crompton; Gabriela Alexe; Doug S Hawkins; Damon Jacobson; Alayne L Brunner; Robert West; Jaume Mora; Kimberly Stegmaier; Paul Khavari; E Alejandro Sweet-Cordero
Journal:  J Clin Invest       Date:  2014-11-17       Impact factor: 14.808

8.  PBX3 is targeted by multiple miRNAs and is essential for liver tumour-initiating cells.

Authors:  Haibo Han; Yantao Du; Wei Zhao; Sheng Li; Dongji Chen; Jing Zhang; Jiang Liu; Zhenhe Suo; Xiuwu Bian; Baocai Xing; Zhiqian Zhang
Journal:  Nat Commun       Date:  2015-09-30       Impact factor: 14.919

Review 9.  miRNA Deregulation in Cancer Cells and the Tumor Microenvironment.

Authors:  Rajesha Rupaimoole; George A Calin; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Discov       Date:  2016-02-10       Impact factor: 39.397

10.  Trim65: a cofactor for regulation of the microRNA pathway.

Authors:  Shitao Li; Lingyan Wang; Bishi Fu; Martin E Dorf
Journal:  RNA Biol       Date:  2014       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.